De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bonesupport Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Bonesupport Holding heeft een totaal eigen vermogen van SEK629.4M en een totale schuld van SEK0.0, wat de schuld-eigenvermogensverhouding op 0% brengt. De totale activa en totale passiva bedragen respectievelijk SEK752.6M en SEK123.2M. De EBIT Bonesupport Holding is SEK74.9M waardoor de rentedekking -65.5 is. Het heeft contanten en kortetermijnbeleggingen van SEK114.6M.

Belangrijke informatie

Verhouding schuld/eigen vermogen

SEK 0

Schuld

Rente dekkingsratio	-65.5x
Contant	SEK 114.58m
Aandelen	SEK 629.41m
Totaal verplichtingen	SEK 123.21m
Totaal activa	SEK 752.62m

Recente financiële gezondheidsupdates

Geen updates

Recent updates

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( SEK477.6M ) BONEXS } overtreffen de korte termijn passiva ( SEK113.8M ).

Langlopende schulden: De kortetermijnactiva BONEXS ( SEK477.6M ) overtreffen de langetermijnschulden ( SEK9.4M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: BONEXS is schuldenvrij.

Schuld verminderen: BONEXS had 5 jaar geleden geen schulden.

Schuldendekking: BONEXS heeft geen schulden en hoeft daarom niet gedekt te worden door de operationele kasstroom.

Rentedekking: BONEXS heeft geen schulden, dus de dekking van rentebetalingen is geen probleem.

Bonesupport Holding Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Recent updates

Bonesupport Holding AB (Publ) Appoints Anna Stegmark as EVP Quality Management & Regulatory Affairs, with Effect from 1 July 2024

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB (Publ) Announces Resignation of Kristina Ingvar as Executive Vice President Quality Management & Regulatory Affairs

Full year 2023 earnings released: EPS: kr3.77 (vs kr1.06 loss in FY 2022)

Bonesupport Holding AB Provides Sales Guidance for the Year 2024

Bonesupport Holding AB (publ) to Report Q1, 2024 Results on Apr 25, 2024

Bone Support Receives “Breakthrough Device Designation” for Cerament® V for the Indication of Bone Infection

Insider recently bought kr426k worth of stock

Second quarter 2023 earnings released: EPS: kr0.08 (vs kr0.25 loss in 2Q 2022)

Forecast breakeven date moved forward to 2023

BONESUPPORT Holding AB Announces Strong Long-Term Results with CERAMENT®G for Severe Open Fractures

Insider recently sold kr701k worth of stock

Forecast breakeven date moved forward to 2023

Chief Executive Officer recently sold kr15m worth of stock

No independent directors

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

Insider recently sold kr1.4m worth of stock

Full year 2022 earnings released: kr1.06 loss per share (vs kr1.34 loss in FY 2021)

No independent directors

No independent directors

Bonesupport Holding AB (publ), Annual General Meeting, Nov 21, 2023

Director recently bought kr203k worth of stock

No independent directors

Bonesupport Holding AB (publ) to Report Q3, 2023 Results on Oct 26, 2023

Third quarter 2022 earnings released

Bonesupport's CERAMENT G Used in First U.S. Patient Cases

Forecast to breakeven in 2023

No independent directors

An unknown buyer acquired unknown minority stakes in Bonesupport Holding AB (publ) (OM:BONEX) from Helena Brandt for SEK 0.84 million.

No independent directors

Bonesupport Holding AB (publ) Announces Publication of Mid- to Long-Term Data Confirming the Sustained Clinical Effectiveness of CERAMENT G

No independent directors

Second quarter 2022 earnings released: kr0.25 loss per share (vs kr0.42 loss in 2Q 2021)

Insider recently bought kr101k worth of stock

Forecast breakeven date moved forward to 2023

Less than half of directors are independent

BONESUPPORT Receives Market Authorization for CERAMENT G in the US

Bonesupport Holding AB (publ) to Report Fiscal Year 2021 Final Results on Apr 13, 2022

BONESUPPORT(TM) Announces Delays Within FDA Postpones CERAMENT G De Novo Decision

Forecast breakeven date pushed back to 2024

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Less than half of directors are independent

Less than half of directors are independent

Third quarter 2021 earnings released

Forecast to breakeven in 2023

Less than half of directors are independent

Bonesupport Announces Supplementary US Denovo Application Submitted

Bonesupport Announces Study Results for its Investigational Device Exemption(IDE) Study, Fortify

Chief Financial Officer recently bought kr87k worth of stock

Less than half of directors are independent

Executive VP of R&D recently sold kr595k worth of stock

BONESUPPORTTM Receives Device Designation for CERAMENT G for the Indication Trauma

Chief Financial Officer recently bought kr210k worth of stock

Chief Financial Officer recently bought kr210k worth of stock

Forecast to breakeven in 2023

Chief Financial Officer recently bought kr210k worth of stock

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Bonesupport Holding AB (publ) Receives Notification from the US Food and Drug Administration

Full year 2020 earnings released: kr1.72 loss per share (vs kr3.10 loss in FY 2019)

Revenue beats expectations

Executive VP of R&D recently bought kr69k worth of stock

Executive VP of R&D recently bought kr69k worth of stock

New 90-day high: kr77.00

New 90-day high: kr75.60

Bonesupport Holding AB (Publ) Announces Resignation of Simon Cartmell from the Board of Directors

Bonesupport Holding AB (publ) to Report First Half, 2021 Results on Jul 15, 2021

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven